Navigation Links
Drive-Through Mastectomies Threaten Patients' Lives
Date:5/22/2008

Says Dr. Marisa Weiss, breast oncologist and BREASTCANCER.ORG founder, in open letter to Congress today about 'Breast Cancer Patient Protection ACT,'

H.R. 758

WASHINGTON, May 22 /PRNewswire-USNewswire/ -- "Mandatory drive-through mastectomies is an unconscionable practice that can endanger patients' recovery and lead to unnecessary complications," says Dr. Marisa Weiss, a leading breast oncologist and Founder and President of Breastcancer.org, in an open letter to Congress today as the "Breast Cancer Patient Protection Act," H.R. 758, is discussed in a House subcommittee hearing. Sixty-five percent of the 125,000 patients undergoing mastectomies each year in the United States are sent home within 24 hours -- a potentially dangerous situation for patients.

The letter, in support of the bill sponsored by Congresswoman Rosa DeLauro of Connecticut, follows:

Dear Representative DeLauro:

I am compelled to write this letter on behalf of my constituency: the

thousands of women who trust me with their lives as their personal doctor,

and the eight million women who trust Breastcancer.org for the best

medical information about breast cancer. As an oncologist -- and as

President and Founder of Breastcancer.org -- I have a unique perspective

on the needs of these brave women.

When a woman has a mastectomy, her life is on the line. And so are her

relationships with all of those she supports ... and those who care for

her. The impact is enormous and the stakes are extremely high.

Therefore, the decision about the length of needed in-hospital recovery

time following breast surgery must be made within the sacred relationship

between a woman and her doctor. Not reduced to a business decision that

overrides a doctor's best judgment and the patient's best interest.

Breast cancer is a serious condition that requires serious -- and<
'/>"/>

SOURCE Breastcancer.org
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop Drive-Through Mastectomies
2. Pharmacists believe drive-through windows contribute to delays, errors
3. Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers
4. Mastectomies on the Increase
5. New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors Care Jeopardized, Local Jobs Lost, National and State Economies Threatened
6. Cleaner Air May Threaten Amazon Rainforest
7. New Lewin Group Analysis: Medicare Cuts for Nursing Facility Care Could Have Economic Impact Up to $4.2 Billion, Threaten Jobs
8. VIDEO from Medialink and CIGNA: Hope Binders Help Parents in the Battle Against Life-Threatening Diseases in Children
9. SEIU Claims Right of Free Speech to Stalk, Harass, and Threaten Registered Nurses According to the California Nurses Association
10. World-first discovery could help treat life-threatening tumors
11. Lung transplants in cystic fibrosis patients with life-threatening bacteria sparks debate at ISHLT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... SEATTLE, Dec. 5 Cell T...q and MTA: CTIC) today announced that that its Boa...Auction" tender offer to,purchase a portion or al...) as,follows: , , -- 4% Convertible Senior...ible Senior Notes due 2011, -- 6.75% Convertib...
(Date:12/4/2008)... , Patients with idiopathic pulmonary fibrosis (I... coronary eventsincluding heart attacksthan people...that analyzed the risk of cardiovascular disease i...00 matched controls. , "If you look at them over...ncreased risk of acute coronary syndrome, which is...
(Date:12/4/2008)... , Early detection of lung disease in cystic fibr...nfants, may be the key to controlling the progress...ew research shows that contrary to previous scient...ts can begin as early as infancy even though lung ...We might be able to stop some of the lung function...
(Date:12/4/2008)... NEW DELHI, India, Dec. 5 /PRNewswire-USNewswire/... Organization today launched a global partnership ...afer, accurate and affordable alternatives. , ...he South Asian Conference on Alternatives to Mercu...rganizations and the Indian NGO Toxics Link. , ...
Breaking Medicine News(10 mins):Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 2Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 3Health News:Double threat: Deadly lung disease also linked to heart attacks 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 3Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2
...ave been able to generate human skin tissues, whic...ncer//. The researchers for the study feel that th...enic potential of genes in development of skin can...f skin cancer that results from the cells called m...
...rom University of Liverpool had proposed that pati...efit from medication.// They say that it is advisa...ileptic patients. Researchers of the study feel th...gnificantly benefit the patients in having a bette...
...eating HIV/AIDS patients with highly active antire...f the cardiac risks involved, says researchers fro...can dramatically improve the quality of a HIV/AIDS...specially helpful for patients with advanced HIV-1...
...suffering from head and neck cancer who are underg...edication to fight oropharyngeal candidiasis. Orop... mouth caused by the yeast Candida. This condition... of the disease are the formation of white plaques...
Other Medicine News:
(Date:12/4/2008)... PARK, Calif., Dec. 4 Long-term da...expected decrease in Mitral Vale Area (MVA),after...tral regurgitation (MR),is not associated with cl...,with two years of follow-up, none of the patien...surgery for mitral stenosis. At 12 months no,impo...
(Date:12/3/2008)...igna front-line data demonstrating potential in ne...e of leukemia to be featured in two oral sessions ...benefits for chronically transfused patients by si...y organs , , - New long-term data from majo...rt on optimal post-surgery treatment strategy, Fem...
(Date:12/3/2008)...GEVILLE, Pa., Dec. 3 Wye...WYE ), announced today that it has submitted a,ma...opean Medicines Agency,(EMEA) for approval to mar...njugate vaccine (PCV13) for infants and young chil...vention of pneumococcal disease (PD) caused by the...
(Date:12/2/2008)...GO, Dec. 3 Researchers ...the circuitry in the area of the brain,responsibl...nts suffering from,stress-related psychiatric dis...day at the annual meeting of the Radiological Soci...ts with major depression and other stress-related ...
Breaking Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 1Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 3Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 1Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 1Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 3Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 1Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 2Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 3Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 5Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 6
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: